Neuburgh Advisers LLC Reduces Position in Zimmer Biomet Holdings Inc (NYSE:ZBH)

Neuburgh Advisers LLC decreased its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 22.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 6,204 shares of the medical equipment provider’s stock after selling 1,760 shares during the period. Neuburgh Advisers LLC’s holdings in Zimmer Biomet were worth $730,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZBH. Personal Wealth Partners purchased a new stake in Zimmer Biomet during the second quarter worth $26,000. TRUE Private Wealth Advisors purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $26,000. Coastal Investment Advisors Inc. increased its holdings in shares of Zimmer Biomet by 271.0% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 187 shares during the last quarter. Private Ocean LLC increased its holdings in shares of Zimmer Biomet by 34.8% during the 2nd quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 80 shares during the last quarter. Finally, Rational Advisors LLC raised its position in shares of Zimmer Biomet by 1,665.2% during the 2nd quarter. Rational Advisors LLC now owns 406 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 383 shares during the period. 89.39% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently commented on ZBH. ValuEngine cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Jefferies Financial Group raised their target price on Zimmer Biomet from $150.00 to $167.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Raymond James lifted their target price on Zimmer Biomet from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Barclays raised Zimmer Biomet from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $117.00 to $140.00 in a research note on Tuesday, July 30th. Finally, Oppenheimer increased their price target on Zimmer Biomet from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet has an average rating of “Buy” and a consensus price target of $142.26.

In related news, insider Didier Deltort sold 360 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the transaction, the insider now owns 1,194 shares in the company, valued at $166,264.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Chad F. Phipps sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $138.28, for a total transaction of $967,960.00. Following the sale, the vice president now directly owns 37,722 shares in the company, valued at $5,216,198.16. The disclosure for this sale can be found here. Insiders have sold 40,391 shares of company stock worth $5,642,274 over the last quarter. Insiders own 0.72% of the company’s stock.

Shares of ZBH stock traded up $1.56 on Wednesday, hitting $140.08. The stock had a trading volume of 29,267 shares, compared to its average volume of 902,693. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.19 and a quick ratio of 0.56. The firm has a market capitalization of $28.44 billion, a P/E ratio of 18.34, a P/E/G ratio of 2.45 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1 year low of $96.99 and a 1 year high of $140.71. The company’s 50 day moving average price is $136.28 and its 200-day moving average price is $125.26.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the prior year, the company earned $1.92 EPS. Zimmer Biomet’s revenue was down .9% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.69%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Economic Reports

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.